Comparative Pharmacology
Head-to-head clinical analysis: LAPATINIB DITOSYLATE versus TASIGNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAPATINIB DITOSYLATE versus TASIGNA.
LAPATINIB DITOSYLATE vs TASIGNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible tyrosine kinase inhibitor that inhibits ErbB-1 (EGFR) and ErbB-2 (HER2) by binding to the ATP-binding pocket, preventing receptor autophosphorylation and downstream signaling.
Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the activity of BCR-ABL, the constitutively activated fusion protein responsible for chronic myeloid leukemia (CML). It also inhibits other kinases including KIT, PDGFR, and DDR1.
Lapatinib ditosylate 1250 mg orally once daily on days 1-21 continuously, plus capecitabine 2000 mg/m2 orally once daily in 2 divided doses on days 1-14 of a 21-day cycle. Alternatively, 1500 mg orally once daily with letrozole 2.5 mg orally once daily continuously.
400 mg orally twice daily approximately every 12 hours. Administer on an empty stomach (no food for at least 2 hours before and 1 hour after dose). Swallow whole with water; do not crush or chew.
None Documented
None Documented
Terminal elimination half-life is 14–24 hours; after repeated dosing, effective half-life is ~24 hours clinically.
Terminal elimination half-life is approximately 90-120 hours, supporting once-daily dosing.
Fecal (approximately 87% as metabolites, with 3% as parent drug); renal (approximately 3% as metabolites).
Primarily fecal (approximately 66-93% of the dose) as unchanged drug and metabolites; renal excretion is minimal (<5% of the dose).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor